The 12-lead mobile ECG

CardioSecur, a personalised mobile 12-lead ECG system with four electrodes for iPhone and iPad, enables patients to monitor their symptoms and transmit the data to their physicians in less than a minute.

Depending on the discrepancy between the two readings, the patient receives an...
Depending on the discrepancy between the two readings, the patient receives an instant message based on a traffic light system: no change to baseline (white); make doctor’s appointment (yellow) and contact a doctor immediately (red)

The system is reported to be ideal for patients with intermittent, difficult to diagnose cardiac symptoms and those who are still symptomatic post-intervention. This also could be use as a tool to monitor drug safety, the manufacturer points out.

‘The patient records a reference ECG reading while sitting calmly with no symptoms. When symptoms occur, the patient takes a control ECG reading for 10 seconds, which is compared to the reference reading. An instant assessment of rhythm, heart rate and perfusion status is performed, see image 2.

The ECG data is uploaded to a database accessible by the patient’s physician immediately, so that viewing the 12-lead ECG data is at the exact moment of the cardiac event (image 1).

In the REDUCE-Trial (Revealing timely ECG changes Decreases the likelihood of Undesirable Cardiac Events-Trial) by ZNA Middelheim, Belgium, 51 patients were given the mobile 12-lead ECG system for a period of three months to record their ECG weekly and when they experienced symptoms. Medical conditions included: recurrent palpitations of unknown origin (41.2%), atypical chest pain (33,3%), angina pectoris (13.7%) and tachycardias of unknown origin (11.8%).

1,237 ECG readings were recorded and CardioSecur diagnosed a new or undiagnosed condition in 10% of the patients. Four were diagnosed with arrhythmias: two with atrial fibrillation; one with monofocal ventricular premature beats with bi- and trigeminia; one with AV nodal re-entry tachycardia.

One ischaemic patient was advised by CardioSecur to make a doctor’s appointment during a control reading. The patient was subsequently diagnosed with a sten-osis of 90%.

All patients received timely and appropriate treatment due to the availability of precise remote 12-lead ECG data at the time of the event.

The study indicates that Cardio-Secur is an important tool for diagnosing and managing patients with cardiac diseases such as rhythm disturbances and ischemic episodes, the manufacturer reports, adding that this paper will be presented in Barcelona this August during the 2014 ESC congress.
 

02.09.2014

Read all latest stories

Related articles

Photo

Listen to your heart 24 hours a day

The ‘Fire of Life’ developed by Schiller is an intuitive visual presentation of frequency-domain heart rate variability (HRV) that makes the assessment of 24-hour results fast and simple.

Photo

Clinical benefit

The future of telemonitoring

The IN-TIME study remains the only major trial to show a clear mortality benefit for remote monitoring in heart failure (HF) patients. A recent analysis by Hussar et al. suggests workflow processes…

Photo

Mobile cMyC analysis

The future POCT heart attack test

Experts report that a new blood test to diagnose heart attacks could be carried out on a hand-held device in the not-too-distant future. The test, devised by a team at Kings College London, uses…

Related products

GE Healthcare – Logiq e

Ultrasound

GE Healthcare – Logiq e

GE Healthcare
GE Healthcare – Vscan Extended

Ultrasound

GE Healthcare – Vscan Extended

GE Healthcare
Hitachi – Arietta Prologue

Ultrasound

Hitachi – Arietta Prologue

Hitachi Medical Systems Europe (Holding) AG
IBA Dosimetry – 2-part PMMA CT-Phantom

Testing Devices

IBA Dosimetry – 2-part PMMA CT-Phantom

IBA Dosimetry GmbH
IBA Dosimetry – 3-part PMMA CT-Phantom

Testing Devices

IBA Dosimetry – 3-part PMMA CT-Phantom

IBA Dosimetry GmbH